Thoughts on the Vitamin E Vaping Controversy - From the Company that Pateneed Vitamin E in Vaping
Revisiting the Vitamin E Acetate Vaping Controversy
As the vaping-related lung injury outbreak (EVALI) unfolded in 2019, vitamin E acetate quickly became a focal point of public health investigations. In this article, Constance Finley, founder of Constance Therapeutics and holder of an early patent involving vitamin E in inhalation formulations, offers important industry perspective on the issue.
Finley explains that while vitamin E acetate was identified in many illicit THC vape products linked to EVALI cases, the problem was not simply the ingredient itself but how it was used. She emphasizes the critical importance of formulation science, manufacturing standards, and product quality, noting that unregulated products often copied patented technologies without understanding the underlying safety requirements.
The article highlights the distinction between pharmaceutical-grade cannabis formulations and illicit vape products, underscoring the need for rigorous research, testing, and responsible manufacturing practices. The controversy serves as a reminder that patient safety depends not only on ingredients, but also on formulation expertise and quality control throughout the production process.
Linked Article by Constance Finley
